BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Montgomery SA, Mansuy L, Ruth A, Bose A, Li H, Li D. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry. 2013;74:363-369. [PMID: 23656841 DOI: 10.4088/jcp.12m08141] [Cited by in Crossref: 42] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Chen L, Greenberg WM, Brand-Schieber E, Wangsa J, Periclou A, Ghahramani P. Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans. Drug Des Devel Ther 2015;9:3293-300. [PMID: 26150701 DOI: 10.2147/DDDT.S85418] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
2 Menezes AM, Murray J, László M, Wehrmeister FC, Hallal PC, Gonçalves H, Assunção MC, Menezes CB, Barros FC. Happiness and depression in adolescence after maternal smoking during pregnancy: birth cohort study. PLoS One 2013;8:e80370. [PMID: 24265817 DOI: 10.1371/journal.pone.0080370] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
3 Cutler AJ, Gommoll CP, Chen C, Greenberg WM, Ruth A. Levomilnacipran Extended-Release Treatment in Patients With Major Depressive Disorder: Improvements in Functional Impairment Categories. Prim Care Companion CNS Disord 2015;17. [PMID: 26644957 DOI: 10.4088/PCC.14m01753] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Bruno A, Morabito P, Spina E, Muscatello MR. The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review. Curr Neuropharmacol 2016;14:191-9. [PMID: 26572745 DOI: 10.2174/1570159x14666151117122458] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
5 Montgomery SA, Gommoll CP, Chen C, Greenberg WM. Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials. CNS Spectr 2015;20:148-56. [PMID: 24902007 DOI: 10.1017/S1092852914000273] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
6 Brunner V, Maynadier B, Chen L, Roques L, Hude I, Séguier S, Barthe L, Hermann P. Disposition and metabolism of [14C]-levomilnacipran, a serotonin and norepinephrine reuptake inhibitor, in humans, monkeys, and rats. Drug Des Devel Ther 2015;9:3199-215. [PMID: 26150694 DOI: 10.2147/DDDT.S80886] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
7 Asnis GM, Henderson MA. Levomilnacipran for the treatment of major depressive disorder: a review. Neuropsychiatr Dis Treat 2015;11:125-35. [PMID: 25657584 DOI: 10.2147/NDT.S54710] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 2.2] [Reference Citation Analysis]
8 Freeman MP, Fava M, Gommoll C, Chen C, Greenberg WM, Ruth A. Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorder. Int Clin Psychopharmacol 2016;31:100-9. [PMID: 26584326 DOI: 10.1097/YIC.0000000000000104] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
9 Huang Q, Zhong X, Yun Y, Yu B, Huang Y. Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder. Neuropsychiatr Dis Treat 2016;12:2707-14. [PMID: 27822042 DOI: 10.2147/NDT.S114955] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Montgomery SA, Mansuy L, Ruth AC, Li D, Gommoll C. The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol 2014;29:26-35. [PMID: 24172160 DOI: 10.1097/YIC.0000000000000009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
11 Sambunaris A, Gommoll C, Chen C, Greenberg WM. Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials. Int Clin Psychopharmacol 2014;29:197-205. [PMID: 24667487 DOI: 10.1097/YIC.0000000000000033] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
12 Gommoll CP, Greenberg WM, Chen C. A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40-120 mg/day) in patients with major depressive disorder. J Drug Assess 2014;3:10-9. [PMID: 27536449 DOI: 10.3109/21556660.2014.884505] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
13 Mago R, Forero G, Greenberg WM, Gommoll C, Chen C. Safety and tolerability of levomilnacipran ER in major depressive disorder: results from an open-label, 48-week extension study. Clin Drug Investig. 2013;33:761-771. [PMID: 23999912 DOI: 10.1007/s40261-013-0126-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
14 Durgam S, Chen C, Migliore R, Prakash C, Thase ME. Relapse prevention with levomilnacipran ER in adults with major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study. Depress Anxiety 2019;36:225-34. [PMID: 30675739 DOI: 10.1002/da.22872] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Sambunaris A, Bose A, Gommoll CP, Chen C, Greenberg WM, Sheehan DV. A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder. J Clin Psychopharmacol. 2014;34:47-56. [PMID: 24172209 DOI: 10.1097/jcp.0000000000000060] [Cited by in Crossref: 47] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
16 Faquih AE, Memon RI, Hafeez H, Zeshan M, Naveed S. A Review of Novel Antidepressants: A Guide for Clinicians. Cureus 2019;11:e4185. [PMID: 31106085 DOI: 10.7759/cureus.4185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
17 Bakish D, Bose A, Gommoll C, Chen C, Nunez R, Greenberg WM, Liebowitz M, Khan A. Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study. J Psychiatry Neurosci. 2014;39:40-49. [PMID: 24144196 DOI: 10.1503/jpn.130040] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 6.3] [Reference Citation Analysis]
18 Zimmerman M, Multach M, Walsh E, Rosenstein LK, Gazarian D, Clark HL. Problems in the Descriptions of the Psychiatric Inclusion and Exclusion Criteria in Publications of Antidepressant Efficacy Trials: A Qualitative Review and Recommendations for Improved Clarity. CNS Drugs 2016;30:185-91. [PMID: 26818632 DOI: 10.1007/s40263-016-0314-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 Hair P, Cameron F, Garnock-Jones KP. Levomilnacipran extended release: first global approval. Drugs 2013;73:1639-45. [PMID: 24000002 DOI: 10.1007/s40265-013-0116-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]